Other anti‐cancer treatments associated with immune‐mediated cytopenias include immune checkpoint inhibitors that reactivate T‐cell mediated immunosurveillance against cancer cells, by targeting programmed death receptor 1 and its ligand (PD1 and PDL1) or CTLA‐4. Here, CTLA4 is linked to cancer.